Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

JACC. Advances

Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation.

2022

Authors: Thomas A, Fang MC, Kogan S, Hubbard CC, Friedman PN, Gong L, Klein TE, Nutescu EA, O'Brien TJ, Tuck M, Perera MA, Schwartz JB

Annals of the rheumatic diseases

POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS.

2022

Authors: P. Robinson, W. P. Maksymowych, L. S. Gensler, M. Rudwaleit, B. Hoepken, L. Bauer, T. Kumke, M. Kim, A. Deodhar

Annals of the rheumatic diseases

POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.

2022

Authors: A. Deodhar, D. Van der Heijde, L. S. Gensler, H. Xu, K. Gaffney, H. Dobashi, W. P. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, M. Oortgiesen, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, X. Baraliakos

Annals of the rheumatic diseases

POS0299 EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL.

2022

Authors: J. Braun, R. Blanco, H. Marzo-Ortega, L. S. Gensler, F. Van den Bosch, S. Hall, H. Kameda, D. Poddubnyy, M. G. H. Van de Sande, D. Van der Heijde, T. Zhuang, A. Stefanska, A. Readie, H. Richards, A. Deodhar

Annals of the rheumatic diseases

OP0154 COMORBIDITY CLUSTERS IN ANKYLOSING SPONDYLITIS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT: DATA FROM THE PSOAS COHORT.

2022

Authors: P. Karmacharya, C. S. Crowson, D. Poudel, J. M. Davis, A. Ogdie, J. Liew, M. Ward, M. Ishimori, M. Weisman, M. Brown, M. Rahbar, M. Hwang, J. D. Reveille, L. S. Gensler

Annals of the rheumatic diseases

OP0023 A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG.

2022

Authors: A. Deodhar, A. Kivitz, M. Magrey, J. A. Walsh, P. J. Mease, M. Greenwald, R. Calheiros, F. Kianifard, C. Elam, K. Nagar, A. Winseck, L. S. Gensler

Annals of the rheumatic diseases

OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.

2022

Authors: D. Van der Heijde, X. Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, L. S. Gensler, M. Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, A. Deodhar

Annals of the rheumatic diseases

OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY.

2022

Authors: R. B. M. Landewé, D. Poddubnyy, P. Rahman, R. Bolce, S. Liu Leage, J. Lisse, A. Leung, S. Y. Park, L. S. Gensler

Journal of pain and symptom management

The Association Between Race and Place of Death Among Persons With Dementia.

2022

Authors: Mayan I, Yaffe K, James J, Hunt LJ

Frontiers in neurology

Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis.

2022

Authors: Block VJ, Waliman M, Xie Z, Akula A, Bove R, Pletcher MJ, Marcus GM, Olgin JE, Cree BAC, Gelfand JM, Henry RG